Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston
4
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
national top stories
new york blog main
san francisco blog main
fda
new york top stories
san diego blog main
san francisco top stories
akero therapeutics
aligos therapeutics
antibiotics
apellis pharmaceuticals
aragon pharmaceuticals
arvinas
astellas pharma
astrazeneca
atlas venture
audentes therapeutics
avidity biosciences
baker brothers life sciences
benzodiazepine
biotech ipos
blackstone group
blepharitis
bluebird bio
boulder/denver
boulder/denver blog main
boulder/denver top stories
carbapenem-resistant enterobacteriaceae
cavion
celgene
cephalgia
chronic hepatitis b virus
corey goodman
What
biotechs
4
×
ipos
ipo
medicines
way
ago
approach
bags
capital
central
chose
close
cns
company
considering
data
device
diseases
disorder
drug
drugs
dyne
early
emerged
expected
experimental
eyes
firms
genetic
having
humans
investing
investors
kept
leads
led
life
limited
long
make
Language
unset
Current search:
biotechs
×
boston
×
biotech
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way